Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
18
MREO Quote, Financials, Valuation and Earnings
Last price:
$0.49
Seasonality move
:
15.38%
Day range:
$0.38 - $0.50
52-week range:
$0.20 - $3.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
154.38x
P/B ratio:
1.69x
Volume:
45.6M
Avg. volume:
21.5M
1-year change:
-86.85%
Market cap:
$78.6M
Revenue:
--
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -74.53% | $3.72 |
|
AUTL
Autolus Therapeutics Plc
|
$24.3M | -$0.40 | 84624.25% | -288.08% | $9.63 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.1M | -$0.94 | 92.62% | -25.75% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$189.5M | -$1.21 | 22.9% | -8.58% | $66.55 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group Plc
|
$0.49 | $3.72 | $78.6M | -- | $0.00 | 0% | 154.38x |
|
AUTL
Autolus Therapeutics Plc
|
$1.81 | $9.63 | $481.7M | -- | $0.00 | 0% | 9.40x |
|
BCYC
Bicycle Therapeutics Plc
|
$6.64 | $21.50 | $460.6M | -- | $0.00 | 0% | 16.23x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.35 | $17.94 | $2M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$3.37 | $104.00 | $14M | -- | $0.00 | 0% | -- |
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$22.51 | $66.55 | $2.2B | -- | $0.00 | 0% | 3.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.603 | 0.12% | 8.09x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 1.504 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
98.95% | 0.967 | 29.68% | 1.61x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$123.3M | -$170.9M | -53.69% | -307.83% | -106.85% | -$92.7M |
Mereo BioPharma Group Plc vs. Competitors
-
Which has Higher Returns MREO or AUTL?
Autolus Therapeutics Plc has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of -373.3%. Mereo BioPharma Group Plc's return on equity of -70.81% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About MREO or AUTL?
Mereo BioPharma Group Plc has a consensus price target of $3.72, signalling upside risk potential of 652.81%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.63 which suggests that it could grow by 432.23%. Given that Mereo BioPharma Group Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe Mereo BioPharma Group Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc4 2 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is MREO or AUTL More Risky?
Mereo BioPharma Group Plc has a beta of 0.358, which suggesting that the stock is 64.214% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.012, suggesting its more volatile than the S&P 500 by 101.185%.
-
Which is a Better Dividend Stock MREO or AUTL?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or AUTL?
Mereo BioPharma Group Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Mereo BioPharma Group Plc's net income of -$7M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 154.38x versus 9.40x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc154.38x -- -- -$7M AUTLAutolus Therapeutics Plc9.40x -- $21.1M -$78.6M
-
Which has Higher Returns MREO or BCYC?
Bicycle Therapeutics Plc has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of -503.67%. Mereo BioPharma Group Plc's return on equity of -70.81% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About MREO or BCYC?
Mereo BioPharma Group Plc has a consensus price target of $3.72, signalling upside risk potential of 652.81%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 223.8%. Given that Mereo BioPharma Group Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Mereo BioPharma Group Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc4 2 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is MREO or BCYC More Risky?
Mereo BioPharma Group Plc has a beta of 0.358, which suggesting that the stock is 64.214% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.42%.
-
Which is a Better Dividend Stock MREO or BCYC?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BCYC?
Mereo BioPharma Group Plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $11.7M. Mereo BioPharma Group Plc's net income of -$7M is higher than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 154.38x versus 16.23x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc154.38x -- -- -$7M BCYCBicycle Therapeutics Plc16.23x -- $11.7M -$58.7M
-
Which has Higher Returns MREO or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of --. Mereo BioPharma Group Plc's return on equity of -70.81% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About MREO or BDRX?
Mereo BioPharma Group Plc has a consensus price target of $3.72, signalling upside risk potential of 652.81%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 7468.14%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc4 2 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is MREO or BDRX More Risky?
Mereo BioPharma Group Plc has a beta of 0.358, which suggesting that the stock is 64.214% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock MREO or BDRX?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BDRX?
Mereo BioPharma Group Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Mereo BioPharma Group Plc's net income of -$7M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 154.38x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc154.38x -- -- -$7M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns MREO or NCNA?
NuCana Plc has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of --. Mereo BioPharma Group Plc's return on equity of -70.81% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About MREO or NCNA?
Mereo BioPharma Group Plc has a consensus price target of $3.72, signalling upside risk potential of 652.81%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 617110.68%. Given that NuCana Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe NuCana Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc4 2 0 NCNANuCana Plc0 1 0 -
Is MREO or NCNA More Risky?
Mereo BioPharma Group Plc has a beta of 0.358, which suggesting that the stock is 64.214% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock MREO or NCNA?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or NCNA?
Mereo BioPharma Group Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Mereo BioPharma Group Plc's net income of -$7M is lower than NuCana Plc's net income of -$378.9K. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 154.38x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc154.38x -- -- -$7M NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns MREO or RARE?
Ultragenyx Pharmaceutical, Inc. has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of -112.81%. Mereo BioPharma Group Plc's return on equity of -70.81% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M -
What do Analysts Say About MREO or RARE?
Mereo BioPharma Group Plc has a consensus price target of $3.72, signalling upside risk potential of 652.81%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $66.55 which suggests that it could grow by 195.65%. Given that Mereo BioPharma Group Plc has higher upside potential than Ultragenyx Pharmaceutical, Inc., analysts believe Mereo BioPharma Group Plc is more attractive than Ultragenyx Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc4 2 0 RAREUltragenyx Pharmaceutical, Inc.15 1 0 -
Is MREO or RARE More Risky?
Mereo BioPharma Group Plc has a beta of 0.358, which suggesting that the stock is 64.214% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.155, suggesting its less volatile than the S&P 500 by 84.518%.
-
Which is a Better Dividend Stock MREO or RARE?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or RARE?
Mereo BioPharma Group Plc quarterly revenues are --, which are smaller than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $159.9M. Mereo BioPharma Group Plc's net income of -$7M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 154.38x versus 3.48x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc154.38x -- -- -$7M RAREUltragenyx Pharmaceutical, Inc.3.48x -- $159.9M -$180.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
